Drug news
NICE rejects Repatha (evolocumab) to treat dyslipidaemia- Amgen
The National Institute for Health and Care Excellence (NICE) has, in preliminary guidance, rejected Repatha (evolocumab) from Amgen, for treatment of dyslipidaemia on the basis that no trial evidence was submitted that the drug has an effect on cardiovascular events. NICE did not accept the Framingham risk equation on the ground that it overestimates CVD risk in a UK population and preferred the NICE recommended QRISK2 assessment tool.
Learning Zones
The Learning Zones are an educational resource for healthcare professionals that provide medical information on the epidemiology, pathophysiology and burden of disease, as well as diagnostic techniques and treatment regimens.